Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach
- PMID: 2579718
- DOI: 10.1002/1097-0142(19850415)55:8<1679::aid-cncr2820550812>3.0.co;2-c
Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach
Abstract
The authors investigated the expression of keratin, carcinoembryonic antigen (CEA), and an epithelial marker derived from milk fat globule membranes in 12 mesotheliomas and 100 diverse adenocarcinomas with immunohistochemical methods. The authors employed a monoclonal antibody to keratin designated as AE1, as well as the following commercially available antisera: rabbit anti-whole human keratin, rabbit anti-CEA, and a monoclonal antibody to an epithelial factor designated as MFG-2. Expression of keratin was found in all the mesotheliomas and adenocarcinomas with antibody AE1 as well as with the rabbit antiserum; CEA was detectable in 65% of the adenocarcinomas but two mesotheliomas also reacted weakly. With antibody MFG-2, positive results were obtained in 85% of the adenocarcinomas and in none of the mesotheliomas. All of 64 (100%) breast-, lung- and ovary-derived adenocarcinomas immunostained positively with antibody MFG-2. This is of particular significance because pulmonary and ovarian adenocarcinoma frequently may be indistinguishable clinically and histologically from epithelial mesothelioma. The authors conclude that antikeratin antibodies are not useful in the distinction of adenocarcinoma from mesothelioma. Because of its greater sensitivity and specificity, MFG-2 is superior to CEA in this differential diagnosis.
Similar articles
-
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.Am J Pathol. 1986 May;123(2):212-9. Am J Pathol. 1986. PMID: 2422942 Free PMC article.
-
The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.Am J Surg Pathol. 1989 Apr;13(4):276-91. Am J Surg Pathol. 1989. PMID: 2648877
-
Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.Cancer. 1991 Feb 1;67(3):655-62. doi: 10.1002/1097-0142(19910201)67:3<655::aid-cncr2820670322>3.0.co;2-j. Cancer. 1991. PMID: 1702354
-
The immunohistochemical diagnosis of epithelial mesothelioma.Hum Pathol. 1999 Mar;30(3):313-23. doi: 10.1016/s0046-8177(99)90011-4. Hum Pathol. 1999. PMID: 10088551 Review.
-
Immunophenotyping of malignant mesothelioma.Am J Surg Pathol. 1997 Dec;21(12):1395-8. doi: 10.1097/00000478-199712000-00001. Am J Surg Pathol. 1997. PMID: 9414182 Review. No abstract available.
Cited by
-
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).Am J Pathol. 1986 Feb;122(2):252-60. Am J Pathol. 1986. PMID: 2418688 Free PMC article.
-
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.Am J Pathol. 1986 May;123(2):212-9. Am J Pathol. 1986. PMID: 2422942 Free PMC article.
-
Immunohistochemistry in the diagnosis of malignant mesothelioma.Virchows Arch A Pathol Anat Histopathol. 1987;411(4):387-93. doi: 10.1007/BF00713385. Virchows Arch A Pathol Anat Histopathol. 1987. PMID: 2442887
-
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.Am J Pathol. 1990 Feb;136(2):421-8. Am J Pathol. 1990. PMID: 2305835 Free PMC article.
-
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.Am J Pathol. 1986 Jun;123(3):497-507. Am J Pathol. 1986. PMID: 3717302 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous